Tinya J. Abrams

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Dirk B. Mendel, Alexander Laird, Xiaohua Xin et al. · PubMed · 2003 · 2K citations

Medicine, Oncology, Pharmacology +15

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

Anne-Marie O'Farrell, Tinya J. Abrams, Helene A. Yuen et al. · Blood · 2003 · 857 citations · Full text

Medicine, Oncology, Pharmacology +11

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

Tinya J. Abrams, Leslie B. Lee, Lesley Murray et al. · PubMed · 2003 · 639 citations

Medicine, Oncology, Pharmacology +17

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

Lesley Murray, Tinya J. Abrams, Kelly R. Long et al. · Clinical & Experimental Metastasis · 2003 · 304 citations

Medicine, Oncology, Pharmacology +14

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.

Tinya J. Abrams, Lesley Murray, Enrico Pesenti et al. · PubMed · 2003 · 252 citations

Medicine, Oncology, Pharmacology +17